Journal profile · Pharmacology & Pharmacy
Idrugs
ISSN 1369-7056 · ENGLAND · Monthly · Founded 1998
Idrugs: subscription journal; review over 12 weeks (community reports); community-reported acceptance: fairly easy.
Scope
Aims, scope and focus
By OpenAlex counts of its recent articles, Idrugs's largest topics are Immunotherapy and Immune Responses, Virus-based gene therapy research and RNA Interference and Gene Delivery, together about 21.4% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Research area (LetPub): Pharmacology & Pharmacy
Main research topics OpenAlex counts of recent articles; shares are approximate
- Immunotherapy and Immune ResponsesImmunology and Microbiology7.1%
- Virus-based gene therapy researchBiochemistry, Genetics and Molecular Biology7.1%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology7.1%
- Chemical Synthesis and AnalysisBiochemistry, Genetics and Molecular Biology7.1%
- Neuroscience and Neuropharmacology ResearchNeuroscience4.8%
- Epilepsy research and treatmentMedicine4.8%
- Computational Drug Discovery MethodsComputer Science4.8%
- Synthesis and biological activityChemistry4.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
Indexed in: no record yet.
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- h-index
- 3OpenAlex ·
- i10-index
- 2OpenAlex ·
- 2-year mean citedness
- 0OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 33 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2022 | 0 | 0 | 1 |
| 2021 | 0 | 0 | 3 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Country or region
- ENGLAND
- Frequency
- Monthly
- Founded
- 1998
- ISSN
- 1369-7056
FAQ
Frequently asked questions about Idrugs
How long does peer review take at Idrugs?
Authors report an average review time of over 12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Is Idrugs open access, and what is the APC?
Idrugs is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .